您搜索了: terapewtikament (马耳他语 - 英语)

m) f’konċentrazzjonijiet fil-plażma terapewtikament relevanti.
250 m) mediated transport at therapeutically relevant plasma concentrations.

formoterol ma jinibixxix l-enzimi cyp450 f’konċentrazzjonijiet terapewtikament rilevanti.
formoterol does not inhibit cyp450 enzymes at therapeutically relevant concentrations.

madankollu, linagliptin mhuwiex mistenni li jitneħħa bi grad terapewtikament sinifikanti mill- emodijalisi jew dijalisi peritoneali.
in addition, linagliptin is not expected to be eliminated to a therapeutically significant degree by hemodialysis or peritoneal dialysis.

formoterol ma jinibixxix l-enzimi cyp450 f’konċentrazzjonijiet terapewtikament rilevanti (ara sezzjoni 5.2).
formoterol does not inhibit the cyp450 enzymes at therapeutically relevant concentrations (see section 5.2).

il-pazjenti għandhom jingħataw il-g-csf terapewtikament mill-aktar fis possibbli wara li tkun skoperta li ngħatat doża eċċessiva.
patients should receive therapeutic g-csf as soon as possible after discovery of overdose.

testijiet prekliniċi u kliniċi in vitro u in vivo wrew li somatropin huwa ekwivalenti terapewtikament għall- ormon tat- tkabbir uman li ġej mill- glandola pitwitarja.
in vitro and in vivo preclinical and clinical tests have demonstrated that somatropin is therapeutically equivalent to human growth hormone of pituitary origin.

studji dwar it- tossiċità waqt u wara t- twelid fil- firien ma wera l- ebda effetti sinifikanti f’ dożi terapewtikament rilevanti.
a peri/ postnatal toxicity study in rats revealed no significant effects at therapeutically relevant doses.

in vitro, sitagliptin ma kienx jinibixxi transport permezz ta ’ oat3 10 (ic50=160 μm) jew p- glycoprotein (sa 250 μm) f’ konċentrazzjonijiet fil- plażma terapewtikament relevanti.
in vitro, sitagliptin did not inhibit oat3 (ic50=160 μ m) or p-glycoprotein (up to 250 μ m) mediated transport at therapeutically relevant plasma concentrations.